The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

Nubia has launched the Nubia Tablet Pro, the company’s latest flagship gaming tablet, in China alongside the camera-centric Z70S Ultra smartphone. It is a cheaper alternative to flagship tablets ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical ...

Discover top tablets for graphic designers in 2025, featuring Wacom, Lenovo, Huion, and Apple devices with precision and versatility for creative work. Graphic design combines art and text, and ...

What’s going on here? A recent US court decision could impact Hims & Hers Health due to halted Semaglutide production, but Truist maintains optimistic revenue forecasts. A court has decided that ...

That came in response to a February lawsuit from a compounding trade group against the Food and Drug Administration's determination that the active ingredient in those drugs, semaglutide ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

"We are deeply disappointed that the (court) misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is ...